Collegium Pharmaceutical (COLL) Receivables - Net (2016 - 2026)

Collegium Pharmaceutical has reported Receivables - Net for 11 years, with the latest figure at $285.1 million in Q2 2026.

• On a quarterly basis, Receivables - Net rose 33.84% year-over-year to $285.1 million in Q2 2026; TTM through Jun 2026 was $285.1 million, a 33.84% increase from a year earlier, with the FY2025 full-year figure at $211.3 million, down 7.53% from the prior year.
• Receivables - Net was $285.1 million for Q2 2026 at Collegium Pharmaceutical, up from $228.8 million in the prior quarter.
• The five-year high for Receivables - Net was $285.1 million in Q2 2026, with the low at $166.3 million in Q1 2022.
• Average Receivables - Net over 5 years is $203.7 million, with a median of $196.5 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Receivables - Net soared 119.21% in 2022, then decreased 15.2% in 2023.
• Over 5 years, Receivables - Net stood at $183.1 million in 2022, then fell by 1.96% to $179.5 million in 2023, then advanced by 27.3% to $228.5 million in 2024, then decreased by 7.53% to $211.3 million in 2025, then jumped by 34.91% to $285.1 million in 2026.
• The last three Receivables - Net figures came in at $285.1 million (Q2 2026), $228.8 million (Q1 2026), and $211.3 million (Q4 2025), per Business Quant data.